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A PEG hydrogel sealant (PleuraSealTM) is used as an adjunct to standard closure of 
pleural air leaks during lung resection surgery and has demonstrated shorter hospi-
talizations (1.7 days fewer) and more rapid removal of chest tubes in clinical studies 
when compared with standard of care (e.g. staples and sutures alone). Our study was 
designed to estimate the potential cost offsets for using PleuraSealTM compared with 
standard of care in 100 hypothetical patients from a UK hospital who had an air leak 
after lung resection surgery using the cost offset from shorter hospital stays balanced 
against the cost for PleuraSealTM. METHODS: We assumed the cost for PleuraSealTM 
to be £360 per treatment applied to all 100 hypothetical patients compared with no 
added cost for standard of care. We then balanced the added cost for PleuraSealTM 
with the reduction in number of hospital days and subsequent costs compared with 
standard of care (£280/day @1.7 days fewer per patient) and calculated the potential 
cost offsets for PleuraSealTM. RESULTS: A hospital with 100 lung resection surgery 
patients with air leaks can expect to save £11,588, or approximately £17 per patient 
when compared to standard of care as patients who had air leaks stayed in hospital 
an average of 1.7 days longer than those without air leaks. CONCLUSIONS: The cost 
for PleuraSealTM is completely offset by the shorter length of hospital stay compared 
with standard of care. PleuraSealTM is a compelling option for hospitals who perform 
lung resection surgeries as the cost of the treatment is completely offset by the reduc-
tion in air leaks and subsequent hospital stay.
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ALBUTEROL AND LEVALBUTEROL USE AND SPENDING IN MEDICARE 
BENEFICIARIES WITH COPD
Puig A, McElligott S, Bergquist H, Doshi J
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: There is inconclusive evidence on the advantages of branded levalb-
uterol over generic albuterol. This study is the ﬁrst to examine the use and spending of 
these two short-acting beta agonists in a nationally representative sample of Medicare 
patients with COPD enrolled in Medicare Part D. The study also examines patient 
characteristics associated with levalbuterol use and compares the use of other Medicare 
Parts B and D covered COPD medications among albuterol and levalbuterol users. 
METHODS: Data were obtained from the 2005–2006 5% Medicare ﬁles linked to the 
2006 Medicare Part D ﬁles. The sample consisted of all fee-for-service beneﬁciaries with 
COPD enrolled in stand-alone Part D plans in 2006. Patient characteristics and other 
COPD medication use were compared across albuterol-only users, levalbuterol-only 
users, and users of both medications. Multinomial logistic regressions identiﬁed the 
independent factors associated with levalbuterol use. RESULTS: There were 5.5 times 
more albuterol users than levalbuterol users; yet total spending on levalbuterol was 
$169 million whereas on albuterol was $50 million in 2006. Levalbuterol-only users 
were more likely to be older, sicker, and reside in the South than albuterol-only users. 
Part B covered nebulizer formulations were more frequently used among levalbuterol-
only users whereas albuterol-only users were more likely to use inhalers under Part D. 
CONCLUSIONS: Our ﬁndings on the striking differences between levalbuterol and 
albuterol users in terms of spending, patient characteristics, geographic region, and 
drug formulation/device type call for further investigations into these issues as well as 
comparative effectiveness and cost-effectiveness studies of these agents.
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COST-UTILITY ANALYSIS OF TIOTROPIUM, MEDICINE FOR CHRONIC 
OBSTRACTIVE PULMONARY DISEASES (COPD) , IN JAPAN
Igarashi A1, Kato Y1, Makita H2, Fukuda T1, Nishimura M2, Tsutani K1
1Tokyo University, Tokyo, Japan, 2Hokkaido University School of Medicine, Sapporo, Japan
OBJECTIVES: To assess cost-effectiveness of tiotropium (Spiriva®), long-acting anti-
cholinergic agent for Chronic Obstructive Pulmonary Diseases (COPD), and ipratro-
pium in Japan. METHODS: A Markov model was constructed to analyze costs and 
Quality-Adjusted Life Years (QALYs) from the health care payers’perspective. Prior to 
construct the model, we assessed utility scores (disease-speciﬁc SGRQ scores and 
EQ-5D scores) and out-patient medicinal costs among COPD patients visiting Hok-
kaido University Hospital, classiﬁed by COPD severity. Medical costs other than 
medicinal costs (diagnosis, hospitalization, exacerbation, etc) were calculated from 
health insurance claim data in Hokkaido University Hospital. We captured costs and 
outcomes for 5 years. In the Markov model, 1 month was set as one cycle. Both costs 
and utility were discounted at 3% annually. We set the numbers of exacerbations and 
QALYs as outcomes. RESULTS: Both of SGRQ scores and EQ-5D scores were signiﬁ-
cantly inﬂuenced by COPD severity. Average EQ-5D scores for severe/very severe and 
moderate patients were 0.68,and 0.87, respectively. Average SGRQ scores for severe/
very severe and moderate patients were 26.1 and 46.1, respectively. COPD severity also 
signiﬁcantly inﬂuenced out-patient medicinal costs. Per diem out-patient medicinal 
costs of severe/very severe and moderate patients were JPY338 and 135, respectively 
(USD1 = JPY92) . As the results of Markov-model analysis, tiotropium would save 
JPY966,000 or USD10,500 (JPY2,604,000 vs. JPY3,570,000) , reduce the numbers of 
exacerbations (0.46 vs. 0.99) and increase 0.258QALY (3.300 vs. 3.042), compared to 
ipratropium.Various sensitivity analysis, both one-way and probabilistic one, showed 
the robustness of the results. From the budget impact analysis, if whole 220,000 COPD 
patient (based on Patient Survey 2005), use tiotropium instead of ipratropium, we 
would save JPY215 bil or USD2.34bil. CONCLUSIONS: Spiriva® for COPD patients 
in Japan, is thought to be cost-effective and would save health care budget.
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COST-UTILITY ANALYSIS OF ANTI-SMOKING TREATMENTS
Brault C1, Rinfret S2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Quebec Heart and Lung Institute, Quebec, 
QC, Canada
OBJECTIVES: Approximately 4.5 million Canadians, or 18.6% of the total popula-
tion, smoke. Although the prevalence of smoking has shown a signiﬁcantly decreasing 
trend, nicotine dependence remains a major public health issue. A number of phar-
macological treatments are available to help smokers quit such as nicotine replacement 
therapies, bupropion and varenicline. The objective of this study was to evaluate the 
incremental cost-utility ratio of pharmacological anti-smoking treatments. METHODS: 
A Markov model based on the Benesco Simulation model (the Beneﬁts of Smoking 
Cessation on Outcomes) was developed to determine the costs and QALYs associated 
with the nicotine replacement therapies, bupropion and varenicline. This cost-utility 
analysis was performed over a lifetime horizon and from a health care system perspec-
tive. The model considers the health status of smokers, recent non-smokers and long-
term non-smokers; the adverse health outcomes of smoking (asthma, chronic 
obstructive pulmonary disease [COPD], coronary heart disease, stroke and lung 
cancer); and deaths from all causes and from smoking. The model also considers 
smoking cessation probabilities associated with anti-smoking treatments, probabilities 
of resuming, probabilities of complications attributable to smoking, and probabilities 
of death. The costs considered are the costs of anti-smoking treatments according to 
recommended doses and amounts reimbursed by the Régie de l’assurance maladie du 
Québec. RESULTS: Nicotine patches, with higher costs and less QALYs, are domi-
nated by both bupropion and varenicline. Nicotine gum is also dominated by bupro-
pion. Varenicline is the most effective of the anti-smoking treatments studied, albeit 
more costly than nicotine gum and bupropion. The incremental cost-utility ratios for 
varenicline versus nicotine gum and bupropion are respectively $825 and $1,235 per 
QALY. CONCLUSIONS: Results show that varenicline is the most effective option 
of the currently available pharmacological anti-smoking treatments, with a very 
acceptable cost-utility ratio.
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COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR 
PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE 
UNITED STATE
Yang M, Tseng WW, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: To assess cost effectiveness of Natalizumab, Glatiramer Acetate (GA) 
and Interferon-β in treating patients diagnosed with relapsing-remitting multiple scle-
rosis (RRMS) from a United States (US) patient’s perspective. METHODS: A 30-year 
Markov model was developed with patients transitioning through health states based 
on the Kurtzke Expanded Disability Status Scale (EDSS). Patient health status was 
deﬁned as mild, moderate, or severe when their EDSS score was 0.0–3.5, 4.0–6.0, 
6.5–9.5, respectively. The model was parameterized with data from an extensive lit-
erature review and was adjusted where necessary to 2008 values. Transition probabili-
ties included patients initial distribution based on EDSS score, relapse rate, mortality 
rate, and progression rate. The total cost included direct (inpatient and outpatient 
admissions, ofﬁce visits to physicians, examinations, medication, medical devices, 
alterations to the care, and informal care from family) and indirect costs (productivity 
losses, and early retirement). The utility considered was Quality Adjusted Life-Year 
(QALY). Sensitivity analyses were conducted on all the transition probabilities at a 
range of ± 25% to check the robustness of the result. RESULTS: Based on the result 
of the 30 year Markov Model, patients treated with Natalizumab spend $1,104,773 
to gain 10.47 QALYs, while patients treated with Interferon- β spend $880,199 to 
obtain 9.88 QALYs and for those patients treated with GA have to pay $907,854 to 
yield 7.07 QALYs, which means patients treated with Natalizumab, Interferon-β or 
GA have to spend $105,517, $89,088, $128,409 respectively to gain one QALY. The 
model suggests that Interferon-β is the most cost-effective DMT agent, with an ICER 
of $380,634 per QALY compared with Natalizumab. Compared with GA, the ICER 
for Interferon- β per QALY was $9,841. Sensitivity analysis showed that the results 
were robust to changes in all parameters. CONCLUSIONS: In our study, Interferon-β 
proved to be more cost effective than both Natalizumab and GA for RRMS patients.
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SMOKING AND WORKPLACE CONSEQUENCES: EVALUATION IN 
FRANCE
Dautzenberg B1, Osman J1, Pibourdin JM2, Charles T3
1OFT, PARIS, France, 2Pierre Fabre, Boulogne cedex, France, 3CREES PFSA, Boulogne, 
France
OBJECTIVES: Tobacco is the primary cause of preventable death in France (66,000 
deaths/Y). Places of work and business are no exception.The objective of this study is 
to gain a better understanding of smoking and its consequences at work, thereby per-
mitting new data to be obtained which will encourage businesses to take smoking into 
account. METHODS: In June 2009, the CSASantéInstitute composed a representative 
sample of the active French population according to the quota method. A total of 1950 
people were interviewed. RESULTS: Of the total active population, there is no signiﬁ-
cant difference according to business size relative to the prevalence of smokers. The 
relationship between smoking and the number of breaks is linear (1 break for 2.5 ciga-
rettes smoked/day). Smokers are subject to even more criticism (because of their break) 
by their colleagues and their hierarchy if they are heavy smokers. Smokers of more than 
1 pack a day tend to be accompanied for their breaks. Smokers have more disrupted 
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employment than non-smokers or ex-smokers: 14.26% of subjects acknowledge having 
had their employment disrupted within the past 6 months.The differences noted 
between the “smokers”, “ex smoker” and “non smoker” populations are statistically 
signiﬁcant (P < 0.001) with prevalence of disrupted employment respectively of 19%, 
15.25% and 11.57% (p < 0.01). It is also noted that the prevalence of smoking during 
work hours is signiﬁcantly more important when the hierarchical superior smokes. 
64.44% smoke during work hours if the hierarchical superior smokes, vs51.17% if the 
hierarchical superior does not smoke ( p < 0.004) CONCLUSIONS: In a population 
representative of persons at work on French soil, this study conﬁrms the data collected 
abroad and in certain businesses in France. Therefore, the justiﬁcation for taking 
smoking into account at the work place is reinforced by its health consequences as well 
as its direct consequences on the work produced.
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HEALTH CARE RESOURCE USE AND TIME TO DIAGNOSIS 
ATTRIBUTABLE TO MANAGING COW MILK ALLERGY IN THE USA: 
CURRENT ESTIMATES AND PREDICTED EFFECTS OF LEGISLATION 
THAT REQUIRES HEALTH CARE COVERAGE FOR AMINO ACID 
FORMULAS
Verdegem PJ1, Samuel P2
1Nutricia Advanced Medical Nutrition, Schiphol Airport, , The Netherlands, 2Nutricia North 
America, Rockville, MD, USA
OBJECTIVES: Cow Milk Allergy (CMA) is estimated to occur in 5% of newborns in 
the USA. Ten states instated legislation that requires health coverage for amino acid 
formulas for CMA. This study aims at assessing the effects of this legislation on health 
care resource use and time to diagnosis for these states and to predict the effects for 
the whole country by extrapolating, should all states adopt similar legislation. Two 
scenarios may explain a better access to amino acid formulas in mandated states: 1) 
amino acid formulas are used as ﬁrst treatment option by specialists when patients 
have not reached symptom resolution at the community paediatrician level, or 2) all 
patients try a maximum of 2 treatment options, before amino acids are prescribed. 
METHODS: This study uses a decision analytical model with resource use data elicited 
from 202 health care professionals combined with probabilistic sensitivity analysis 
using a beta distribution with 20% standard deviation around the means to assess 
uncertainty of the input parameters. RESULTS: Health care resource use attributable 
to CMA treatment in the combined 50 states amounts to 371,043 community paedia-
trician visits, 3,695 hospital paediatrician visits, 17,704 outpatient paediatric gastro-
enterologist visits and 6,779 allergist visits. 6,216,006 days are spent to reach 
symptom resolution. The predicted reduction in number of total specialist visits for 
the USA for scenario 1 is 4,532, and 9,888 for scenario 2. The reduction in time to 
diagnosis amounts to 84,188 days for scenario 1 and 292,783 days for scenario 2. 
CONCLUSIONS: Legislation requiring coverage for amino acids after diagnosis of 
CMA is likely to reduce health care resource use in the USA, free up time of health 
care professionals to use in an alternative way, as well as reduce the time to diagnosis, 
which reduces the suffering of children with CMA.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes 
Studies
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RELATIONSHIP BETWEEN DAILY DOSING FREQUENCY, COMPLIANCE, 
HEALTH CARE RESOURCE USE, AND COSTS: EVIDENCE FROM THE 
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD)
Toy EL1, Beaulieu NU2, McHale JM2, Welland TR1, Plauschinat C3, Swensen A3, Duh MS2
1Analysis Group, Lakewood, CO, USA, 2Analysis Group, Boston, MA, USA, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To assess the relationship between the daily dosing frequency (DDF) 
of COPD pharmacotherapies and treatment compliance; to estimate the effect of 
compliance on health care resource utilization (HCRU) and costs. METHODS: COPD 
patients were identiﬁed using a health insurance claims database covering 8 million 
lives (1999–2006). Patients were stratiﬁed based on the recommended DDF (QD, BID, 
TID, QID) of their ﬁrst COPD drug claim post COPD diagnosis. Compliance was 
measured using proportion of days covered (PDC). HCRU outcomes included inpa-
tient days and medical visits (inpatient, outpatient, and emergency room). A multivari-
ate regression model assessed the relationship between compliance and one-year 
HCRU controlling for demographics, comorbidities, and baseline resource use. Unit 
health care costs were obtained from the 2005 Medical Expenditure Panel Survey data 
and adjusted to 2008 dollars. Total costs were modeled by multiplying unit costs by 
the observed HCRU. RESULTS: Sample sizes ranged from 3,678 (QD) to 25,011 
(BID). Compliance was strongly correlated with DDF: PDC over one year for QD, 
BID, TID, and QID patients was 43%, 37%, 30%, and 23%, respectively (all p < 
0.001 vs. QD). Multivariate analysis showed that one-year compliance was correlated 
with HCRU. For 1,000 COPD patients, a 5 percentage point increase in PDC reduced 
the number of inpatient visits by 2.5%, hospital inpatient days by 3.1%, and emer-
gency room visits by 1.8%; the estimated number of outpatient visits increased by 
0.2% (p < 0.001 for all comparisons). This increase in compliance yielded approxi-
mately $300,000 in cost savings from decreased HCRU. CONCLUSIONS: COPD 
patients who initiated treatment with QD dosing had signiﬁcantly higher compliance 
than those with more frequent dosings. Patients with higher compliance were found 
to incur fewer hospital- and emergency room-related visits. In a hypothetical cohort 
of 1,000 COPD patients, increasing PDC by 5 percentage points would save $300,000 
per year, mostly from reduced hospital visits.
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RELATIONSHIP OF COST-SHARING LEVELS TO ADHERENCE WITH 
DUAL-CONTROLLER THERAPY AMONG ASTHMA PATIENTS
Vaidya V1, Hong SH2, White-Means S2, Gourley D3
1University of Toledo, Toledo, OH, USA, 2University of Tennessee Health Science Center, 
Memphis, TN, USA, 3University of Tennessee, Memphis, TN, USA
OBJECTIVES: To analyze the effect of cost-sharing levels and other co-variates on 
adherence to asthma controller therapy among patients with moderate persistent 
asthma. METHODS: Data for this study came from a large administrative claims 
dataset (MarketScan). The selection criteria for this study included patients with at 
least one asthma-related outpatient claim (ICD-9-CM 493.XX).Asthma patients on 
dual controller therapy (ICS and LABA or ICS and LTRA) were identiﬁed and the 
initial date of LABA or LTRA prescription served as the index date.Patients were 
required to be continuously enrolled during the entire study period. The medication 
possession ratio (MPR) was used to measure adherence. RESULTS: A total of 1,447 
patients met the study criteria. Of these patients, 898 (62.1%) were initiated on 
ICS+LABA, and 549 (37.9%) were initiated on ICS+LTRA. The average combined 
adherence to controller regimen was 0.45 (median = 0.43) for the entire study popula-
tion.The odds of having increased adherence (MPR above the median) decreased 
signiﬁcantly with the increase in cost-sharing levels. Compared with patients having 
$0–15 cost-sharing level, patients having $16–30 (odds ratio [OR] = 0.449, 95% CI 
= 0.312–0.616 ), $31–45 (OR = 0.246, 95% CI = 0.168–0.358) and $46 and more 
(OR = 0.131, 95% CI = 0.084–0.206) had lower odds of having appropriate adher-
ence. Type of insurance plan, geographical region, and type of controller therapy were 
also signiﬁcantly associated with adherence. CONCLUSIONS: Even though the need 
to be adherent is greater among patients on dual-controller therapy, cost-sharing levels 
played an important role in level of adherence. The study also found the type of 
controller medication to be associated with the adherence to the therapy.
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TRANSLATING THE EXACT: ENSURING CONCEPTUAL EQUIVALENCE 
ACROSS MULTIPLE CULTURES
Arnold BJ1, Murray L2, Herzberg T1, Roberts L2, Leidy N2
1FACIT.org Translations, Elmhurst, IL, USA, 2United BioSource Corporation, Bethesda, 
MD, USA
OBJECTIVES: Translation and linguistic validation of patient reported outcomes 
(PRO) measures is an essential component of research methodology in preparation 
for multinational clinical trials. The EXAcerbations of Chronic Pulmonary Disease 
Tool (EXACT) was designed to evaluate frequency, severity, and duration of acute 
exacerbations of chronic obstructive pulmonary disease (COPD), including chronic 
bronchitis. The EXACT is 14-item daily diary designed to be administered on an 
electronic handheld device (e.g. personal digital assistant (PDA)). The objective of this 
work was to translate and linguistically validate the EXACT for use in 17 countries: 
Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Hungary, Japan, Korea, The 
Netherlands, Peru, Philippines, Poland, Romania, South Africa, Taiwan and UK. 
METHODS: The EXACT was translated according to industry standard methodol-
ogy, including detailed item deﬁnitions based on qualitative work conducted during 
instrument development. Five patients per country completed the respective translated 
questionnaire and participated in a cognitive interview. Interviews were conducted 
using a standardized guide to assess the understandability, cultural relevance, and 
appropriateness of wording of the translations. Qualitative analyses were performed 
to ensure that the content validity of the EXACT was maintained and equivalent 
across language versions. RESULTS: The study sample consisted of 90 patients with 
COPD (57.7% male). Mean age was 63 years. The sample consisted of patients who 
speak 14 languages collectively. All EXACT translations were well understood and 
proved relevant to the patients in this sample. Of interest, terms such as, “chest feel 
tight”, and “short of breath” were understood and described similarly by participants 
across countries. CONCLUSIONS: The results indicate the EXACT translations were 
conceptually equivalent to the English source version and easily understood by the 
target population for all 17 countries. We consider these translations acceptable for 
PRO assessment in international research and clinical trials, bringing the total number 
of validated EXACT translations to 25.
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EVALUATING PEOPLE’S PREFERENCES FOR PREVENTIVE TREATMENT 
OF LATENT TUBERCULOSIS INFECTION USING A DISCRETE CHOICE 
EXPERIMENT
Guo N1, Marra F1, Marra C1, Elwood K2, FitzGerald M1
1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Center for 
Disease Control, Vancouver, BC, Canada
OBJECTIVES: This study aimed to quantify the preferences of people with latent 
tuberculosis infection (LTBI) when making decisions on whether to accept preventive 
treatment with Isoniazid and to understand the trade-off nature of their decision-
making. METHODS: English-speaking adults with LTBI were recruited from the 
tuberculosis (TB) clinic at British Columbia Centre for Disease Control. A custom-
designed discrete choice experiment (DCE) measured preferences for 6 attributes of 
preventive treatment decision-making. A conditional logit model was performed to 
estimate respondents’ preferences. RESULTS: Among the 152 participants, 142 
(93.4%) with valid DCE responses were included for data analyses. Their average age 
